IACH News Podcasts

Give the high rate of advances in the field of clinical hematology, the IACH News initiative enables experts in the field and key opinion leaders share the most up to date information in a timely manner, and in a format that is, focused, engaging and easy to access.

May 14th 2024- Prof. Didier Blaise- Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis

CME Congresses .

May 14th 2024- Prof. Didier Blaise- Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis

May 7th 2024- Prof. Ibrahim Yakoub-Agha- Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

CME Congresses .

May 7th 2024- Prof. Ibrahim Yakoub-Agha- Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

April 30th 2024- Dr. Fadi Haddad & Prof. Elias Jabbour- Phase 2 Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission

CME Congresses .

April 30th 2024- Dr. Fadi Haddad & Prof. Elias Jabbour- Phase 2 Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission

April 17th 2024- Prof. Nigel Russell- Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

CME Congresses .

April 17th 2024- Prof. Nigel Russell- Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

March 25th 2024- Prof. Olaf Penack- Prophylaxis and Management of Graft-Versus-Host Disease After Stem-Cell Transplantation for Haematological Malignancies: Updated Consensus Recommendations of the European Society for Blood and Marrow Transplantation

CME Congresses .

March 25th 2024- Prof. Olaf Penack- Prophylaxis and Management of Graft-Versus-Host Disease After Stem-Cell Transplantation for Haematological Malignancies: Updated Consensus Recommendations of the European Society for Blood and Marrow Transplantation

March 20th 2024- Prof. Michael Schmitt – Efficacy and safety of extended duration letermovir prophylaxis in recipients of hematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial

CME Congresses .

March 20th 2024- Prof. Michael Schmitt – Efficacy and safety of extended duration letermovir prophylaxis in recipients of hematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial

March 11th 2024- Dr. Adi Zoref Lorenz – Malignancy-Associated Hemophagocytic Lymphohistiocytosis in Sweden: Incidence, Clinical Characteristics, and Survival

CME Congresses .

March 11th 2024- Dr. Adi Zoref Lorenz – Malignancy-Associated Hemophagocytic Lymphohistiocytosis in Sweden: Incidence, Clinical Characteristics, and Survival

April 10th 2024- Dr. Ofir Wolach- Molecular MRD is Strongly Prognostic in Patients with NPM1-Mutated AML Receiving Venetoclax-Based Nonintensive Therapy

CME Congresses .

April 10th 2024- Dr. Ofir Wolach- Molecular MRD is Strongly Prognostic in Patients with NPM1-Mutated AML Receiving Venetoclax-Based Nonintensive Therapy

March 6th 2024- Prof. Katy Rezvani – Safety, Efficacy and Determinants of Response of Allogeneic CD19-Specific CAR-NK Cells in CD19+ B Cell Tumors: a Phase 1/2 Trial

CME Congresses .

March 6th 2024- Prof. Katy Rezvani – Safety, Efficacy and Determinants of Response of Allogeneic CD19-Specific CAR-NK Cells in CD19+ B Cell Tumors: a Phase 1/2 Trial

Feb 26th 2024- Prof. Marion Subklewe- Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

CME Congresses .

Feb 26th 2024- Prof. Marion Subklewe- Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy